A core facility for advanced immune profiling techniques.
Official title: HIPC U19 Adaptive Immunophenotyping Core
Funded at Benaroya Research Inst at Virginia Mason · NIH-11295554 · Data updated 2026-11-12
This study is all about using new techniques to take a closer look at your immune system, helping doctors understand how it works in different health conditions, so they can create better tests and personalized treatments just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 29, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $406,158 |
| NIH project number | 5U19AI167891-04 |
| Project ID | NIH-11295554 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with immune-related conditions or those seeking personalized treatment options based on their immune system characteristics.
✕Less likely to help
Patients without immune-related conditions or those not interested in immune profiling may not receive benefits from this research.
What this research studies
This research focuses on developing and providing advanced immunophenotyping techniques to better understand immune responses. By utilizing cutting-edge technologies, the project aims to analyze immune cell populations and their functions in various health conditions. Patients may benefit from improved diagnostic tools and personalized treatment strategies based on their immune profiles.
Why it matters
Potential benefit: If successful, this research could lead to more accurate immune profiling, enhancing personalized medicine approaches for patients.
How similar studies have gone: Similar research in immune profiling has shown promise in improving patient outcomes, indicating a potential for success in this approach.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Wambre, Erik — Benaroya Research Inst at Virginia Mason
- Study coordinator: Wambre, Erik
Related research
Other NIH-funded projects on the same topics.
-
T cells and the switch from pre-autoimmunity to autoimmune disease
A study following people at risk for type 1 diabetes and people with Down syndrome to understand how certain T cells may shift toward causing autoimmune disease.
-
Genetic and epigenetic control of T cell function in autoimmune disease
This grant aims to understand how genetic and epigenetic changes affect how T cells behave in autoimmune diseases to find ways to reduce harmful immune responses.
-
Immune Tolerance Network (ITN) for immune tolerance therapies across autoimmune and allergic diseases
A national network runs clinical trials to test new immune-tolerance therapies that could help people with autoimmune and allergic diseases.
-
Immune Tolerance Network for safer, more effective immune therapies
A nationwide network tests new immune therapies to help people with autoimmune diseases, allergies, and transplant patients reach better control of their immune system.
-
Immune tolerance research network for safer transplant and autoimmune therapies
A national effort tests new treatments that make the immune system tolerate transplanted organs and fight autoimmune and allergic diseases more safely.
-
Immune Tolerance Network for allergy, autoimmunity, and transplantation
A large NIH program tests new immune-tolerance therapies to help people with autoimmune diseases, allergies, and transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.